A randomized placebo controlled trial of vitamin E for alcoholic hepatitis

Esteban Mezey, James John Potter, Lynda Rennie-Tankersley, Juan Caballeria, Albert Pares

Research output: Contribution to journalArticle

Abstract

Background/Aims: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial. Methods: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial. Results: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-κB binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P <0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study. Conclusions: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.

Original languageEnglish (US)
Pages (from-to)40-46
Number of pages7
JournalJournal of Hepatology
Volume40
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Alcoholic Hepatitis
Vitamin E
Randomized Controlled Trials
Placebos
Serum
Hyaluronic Acid
Collagen Type III
Liver
Liver Function Tests
Prothrombin Time
Transaminases
Bilirubin
Serum Albumin
Monocytes
Creatinine
Reference Values
Therapeutics
Peptides

Keywords

  • α-Tocopherol
  • Aminoterminal peptide of type III procollagen
  • Hyaluronic acid
  • Nuclear factor-κB

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. / Mezey, Esteban; Potter, James John; Rennie-Tankersley, Lynda; Caballeria, Juan; Pares, Albert.

In: Journal of Hepatology, Vol. 40, No. 1, 01.2004, p. 40-46.

Research output: Contribution to journalArticle

Mezey, Esteban ; Potter, James John ; Rennie-Tankersley, Lynda ; Caballeria, Juan ; Pares, Albert. / A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. In: Journal of Hepatology. 2004 ; Vol. 40, No. 1. pp. 40-46.
@article{6b76dff431a643949e07ab5c87965640,
title = "A randomized placebo controlled trial of vitamin E for alcoholic hepatitis",
abstract = "Background/Aims: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial. Methods: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial. Results: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-κB binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P <0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study. Conclusions: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.",
keywords = "α-Tocopherol, Aminoterminal peptide of type III procollagen, Hyaluronic acid, Nuclear factor-κB",
author = "Esteban Mezey and Potter, {James John} and Lynda Rennie-Tankersley and Juan Caballeria and Albert Pares",
year = "2004",
month = "1",
doi = "10.1016/S0168-8278(03)00476-8",
language = "English (US)",
volume = "40",
pages = "40--46",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - A randomized placebo controlled trial of vitamin E for alcoholic hepatitis

AU - Mezey, Esteban

AU - Potter, James John

AU - Rennie-Tankersley, Lynda

AU - Caballeria, Juan

AU - Pares, Albert

PY - 2004/1

Y1 - 2004/1

N2 - Background/Aims: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial. Methods: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial. Results: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-κB binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P <0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study. Conclusions: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.

AB - Background/Aims: The effect of vitamin E administration on clinical and laboratory parameters of liver function and on markers of fibrogenesis was assessed in patients with mild to moderate alcoholic hepatitis in a double blind placebo controlled randomized trial. Methods: Twenty-five patients received 1000 I.U. of vitamin E per day, while 26 patients received placebo for 3 months. The patients were followed for 1 year after entry into the trial. Results: Vitamin E did not result in significant greater decreases in serum aminotransferases and serum bilirubin or in greater increases in serum albumin as compared with placebo. Prothrombin time did not change, while serum creatinine remained in the normal range. Monocyte nuclear nuclear factor-κB binding activity decreased in patients who remained abstinent, regardless of whether they received vitamin E. As regards markers of hepatic fibrogenesis, vitamin E treatment decreased serum hyaluronic acid (P <0.05) while serum aminoterminal peptide of type III procollagen did not change in either group. Four patients in the treatment group and five in the placebo group died during the 1-year study. Conclusions: Vitamin E treatment improves serum hyaluronic acid but has no beneficial effects on tests of liver function in patients with mild to moderate alcoholic hepatitis.

KW - α-Tocopherol

KW - Aminoterminal peptide of type III procollagen

KW - Hyaluronic acid

KW - Nuclear factor-κB

UR - http://www.scopus.com/inward/record.url?scp=0347950972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347950972&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(03)00476-8

DO - 10.1016/S0168-8278(03)00476-8

M3 - Article

C2 - 14672612

AN - SCOPUS:0347950972

VL - 40

SP - 40

EP - 46

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 1

ER -